{
  "abstract": "Background and Importance Ferric carboxymaltose (FCM) is indicated when rapid iron replenishment is required. The maximum cumulative weekly dose is 1000 mg. Although medium-term effects on haemoglobin (Hb) are well characterised, short-term response remains underexplored.Aim and Objectives To evaluate different FCM administration protocols according to Hb changes at days 1 and 5-7 post-infusion, and to assess associations between patient related covariates and Hb increase (ΔHb).Material and Methods A retrospective observational study was conducted at a tertiary hospital (January–August 2025). Data were collected from Orion Clinic and analysed using RStudio. Variables included total dose, sex, baseline Hb (Hb0), Hb day1(Hb1) and days 5-7 (Hb5–7) post-infusion, ΔHb, bleeding presence, postoperative status, transfusions and age.Administration protocols were:G0=1000 mg single doseG1=500 mg single doseG2=500+500 mg on consecutive daysG3=500+500 mg on non-consecutive daysMissing data were addressed using multiple imputation by chained equations (MICE). ΔHb was analysed using ANCOVA, adjusting for Hb0, bleeding, surgery, transfusions and age. Estimated marginal means were compared with Tukey’s adjustment (TK).Results A total of 158 patients (58% women), mean age 66.0±20.4 years, mean Hb0=8.69g/dL, were included.A bleeding was reported in113 patients had bleeding and in 61 patients FCM was required after a surgery. 58 patients required transfusion.Group distribution:G0: n=54G1: n=53G2: n=19G3: n=32Adjusted analyses revealed no significant differences in ΔHb at day 1 or 5–7 between groups (p>0.05). A non-significant trend towards higher ΔHb was observed in G3 compared to G0 (p=0.09), not maintained persisting after TK (p>0.33).Hb0 was inversely associated with ΔHb in days 1 and 5-7(p<0.001). Bleeding was positively associated with greater ΔHb (day1: p = 0.009; day5–7: p = 0.011). No other covariates were significant.Conclusion and Relevance No significant short–term differences in ΔHb were found between FCM administration regimens. Therefore, dose fractionation may not provide additional short–term benefit in terms of Hb recovery.Hb0 seems to influence treatment response, due to higher Hb0 showed smaller short–term increasesBleeding was associated with greater ΔHb, highlighting the importance of the follow–up of these patients.Limitations such as patient follow–up, uncontrolled bleeding and retrospective data collection may have influenced results. Future studies of Hb after FCM could optimise treatment strategies and patient selection.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital General Universitario D’elx, Servicio De Farmacia, Elche, Spain"
      ],
      "name": "M Yago Giménez"
    },
    {
      "affiliations": [
        "Hospital General Universitario D’elx, Servicio De Farmacia, Elche, Spain"
      ],
      "name": "M Lumbreras Such"
    },
    {
      "affiliations": [
        "Hospital General Universitario D’elx, Servicio De Farmacia, Elche, Spain"
      ],
      "name": "I Castejón Grao"
    },
    {
      "affiliations": [
        "Hospital General Universitario D’elx, Servicio De Farmacia, Elche, Spain"
      ],
      "name": "C Matoses Chirivella"
    },
    {
      "affiliations": [
        "Hospital General Universitario D’elx, Servicio De Farmacia, Elche, Spain"
      ],
      "name": "L Peral Ballester"
    },
    {
      "affiliations": [
        "Hospital General Universitario D’elx, Servicio De Farmacia, Elche, Spain"
      ],
      "name": "AC Murcia Lopez"
    }
  ],
  "title": "4CPS-257 Comparison of ferric carboxymaltose administration regimens according to haemoglobin",
  "uid": "97e8bda3-14f4-5e10-8da3-92853448062e"
}